Nuvig Therapeutics

Rebalancing immune function for autoimmune diseases

Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$161.0M
Last Round
$161.0M Series BDec 2024
Rounds
1

About

Nuvig Therapeutics is a biopharma developing immune modulators for chronic inflammatory and autoimmune diseases. Lead NVG-2089 in Phase 2 for CIDP.

Tech & App Stack

Tech & App Stack is available on paid plans

Upgrade to Silver or higher to reveal the full technology and app stack for any company.

View pricing

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

Series BSeries BDec 2024
$161.0M

Investors

Sign up to view investors

Create a free account to see which investors have funded this company.

Create Free Account

Similar Companies